

## Module: QScript Learning – Quetiapine

### Course: PRESCRIBER AND DISPENSER TRAINING

#### Suggested Citation:

Insight: Centre for AOD Training and Workforce Development. Quetiapine. QScript Learning. Prescriber and dispenser training [Internet]. 2023. Available from: <https://insight.qld.edu.au/training/elearning>.

1. Therapeutic Goods Administration. Australian public assessment report for quetiapine (as fumarate): Australian Government, Department of Health and Ageing, Therapeutic Goods Administration; 2010 [cited 2020 5 February]. Available from: <https://www.tga.gov.au/auspar/auspar-quetiapine-fumarate>.
2. Therapeutic Goods Administration. Seroquel® (quetiapine fumarate) film coated tablets [cited 2019 9 Dec]. Available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07764-3&d=201912161016933>.
3. Chow ES, Zangeneh-Kazemi A, Akintan O, Chow-Tung E, Eppel A, Boylan K. Prescribing Practices of Quetiapine for Insomnia at a Tertiary Care Inpatient Child and Adolescent Psychiatry Unit: A Continuous Quality Improvement Project. *J Can Acad Child Adolesc Psychiatry*. 2017;26(2):98-103.doi:
4. Boldingh Debernard KA, Frost J, Roland P-DH. Quetiapine is not a sleeping pill. *Tidsskrift for Den norske legeforening (Journal of the Norwegian Medical Association)*. 2019.doi: 10.4045/tidsskr.19.0205
5. Royal Australian College of General Practitioners. Prescribing drugs of dependence in general practice, Part B - benzodiazepines. Melbourne, VIC: RACGP; 2015 [cited 2019 Aug 1]. Available from: <https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/drugs-of-dependence>.
6. Psychotropic Expert Group. Anxiety and associated disorders [cited 2023 14 Feb]. Available from: [https://tgldcdp.tg.org.au/viewTopic?topicfile=anxiety-disorders#toc\\_d1e189](https://tgldcdp.tg.org.au/viewTopic?topicfile=anxiety-disorders#toc_d1e189).
7. Naguy A. Low-dose quetiapine complements stimulant response in attention deficit hyperactivity disorder and more. *Ther Adv Psychopharmacol*. 2016;6(6):384-5.doi: 10.1177/2045125316672545
8. Dold M, Aigner M, Klabunde M, Treasure J, Kasper S. Second-Generation Antipsychotic Drugs in Anorexia Nervosa: A Meta-Analysis of Randomized Controlled Trials. *Psychother Psychosom*. 2015;84(2):110-6.doi: 10.1159/000369978
9. Kelly M, Dornan T, Pringsheim T. The lesser of two evils: a qualitative study of quetiapine prescribing by family physicians. *CMAJ open*. 2018;6(2):E191-e6.doi: 10.9778/cmajo.20170145
10. Brett J. Concerns about quetiapine. *Australian Prescriber*. 2015;38(3):95-7.doi: 10.18773/austprescr.2015.032
11. Brett J, Anthony C, Kamel B, Day RO. Off-label quetiapine prescribing in general hospital inpatients: an Australian experience. *Journal of Pharmacy Practice and Research*. 2020;50(4):316-20.doi: 10.1002/jppr.1608
12. Garrity A, Foenander P, Howson B, Andrews C, Brett J. Concerns about quetiapine. *Australian prescriber*. 2015;38(6):188-90.doi: 10.18773/austprescr.2015.073
13. Khasawneh FT, Shankar GS. Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia. *Cardiol Res Pract*. 2014;2014:273060-.doi: 10.1155/2014/273060
14. Australian Medicines Handbook. Australian medicines handbook 2019. Buckley N, editor. Adelaide, SA: Australian Medicines Handbook; 2019.
15. Curry DE, Richards BL. A Brief Review of Quetiapine. *American Journal of Psychiatry Residents' Journal*. 2022;18(2):20-2.doi: 10.1176/appi.ajp-rj.2022.180207
16. Jalota R, Bond C, José RJ. Quetiapine and the development of the metabolic syndrome. *QJM*. 2015;108(3):245-7.doi: 10.1093/qjmed/hcs142
17. Khodoruth MAS, Abdo AKA, Ouanes S. Quetiapine-Induced Thyroid Dysfunction: A Systematic Review. *The Journal of Clinical Pharmacology*. 2022;62(1):20-35.doi: <https://doi.org/10.1002/jcph.1960>

18. Behm C, Case A, Krishnamoorthy A, Pegg G. Off-label prescribing. *Medicines Safety Update*. 2017 [cited 2019 16/12]; 8(4):[3 p.]^pp.]. Available from: <https://www.tga.gov.au/sites/default/files/medicines-safety-update-volume-8-number-4-august-september-2017.pdf>.
19. Arts M, Petrykiv S, Fennema J, De Jonge L. Off-label prescriptions of quetiapine for sleep disturbances. *European Psychiatry*. 2017;41:S749-S50.doi: 10.1016/j.eurpsy.2017.01.1392
20. Almeida F, Albuquerque E, Murta I. Delirium Induced by Quetiapine and the Potential Role of Norquetiapine. *Frontiers in Neuroscience*. 2019;13(896).doi: 10.3389/fnins.2019.00886
21. Chiappini S, Schifano F. Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database. *Journal Of Clinical Psychopharmacology*. 2018;38(1):72-9.doi: 10.1097/JCP.0000000000000814
22. Vento AE, Kotzalidis GD, Cacciotti M, Papanti GD, Orsolini L, Rapinesi C, et al. Quetiapine abuse fourteen years later: Where are we now? A systematic review. *Substance Use & Misuse*. 2019:1-10.doi: 10.1080/10826084.2019.1668013
23. Soeiro-De-Souza MG, Dias VV, Missio G, Balanzá-Martinez V, Valiengo L, Carvalho AF, et al. Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review). *Experimental and Therapeutic Medicine*. 2015;9(3):643-52.doi: 10.3892/etm.2015.2213
24. Malhi GS, Bell E, Porter RJ. Serial quelling: The typical use of atypical antipsychotics? *Australian & New Zealand Journal of Psychiatry*. 2019;53(6):495-8.doi: 10.1177/0004867419851874
25. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes. *FOCUS*. 2016;14(2):244-65.doi: 10.1176/appi.focus.140202
26. Maan JS, Saadabadi A. Quetiapine [cited 2020 May 26]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459145/>.
27. Chow ES, Zangeneh-Kazemi A, Akintan O, Chow-Tung E, Eppel A, Boylan K. Prescribing practices of quetiapine for insomnia at a tertiary care inpatient child and adolescent psychiatry unit: a continuous quality improvement project. *J Can Acad Child Adolesc Psychiatry*. 2017 [cited 2020 30 June]; 26(2):[98-103 p.]^pp.]. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510938/>.
28. Cornelis C, Van Gastel A, Dumont G, Coppens V, Sabbe B, Morrens M, et al. A case of dose escalation of quetiapine in persistent insomnia disorder. *Acta Clinica Belgica*. 2017;72(5):346-8.doi: 10.1080/17843286.2016.1252546
29. Psychotropic Expert Group. Insomnia [cited 2023 14 Feb]. Available from: [https://tqldcdp.tg.org.au/viewTopic?topicfile=insomnia-parasomnias-jet-lag#toc\\_d1e47](https://tqldcdp.tg.org.au/viewTopic?topicfile=insomnia-parasomnias-jet-lag#toc_d1e47).
30. National Institute for Health and Care Excellence. Generalised anxiety disorder: quetiapine. Evidence summary [ESUOM12] [cited 2020]. Available from: <https://www.nice.org.uk/advice/esuom12/chapter/Key-points-from-the-evidence>.
31. Maneeton N, Maneeton B, Woottitluk P, Likhitsathian S, Suttajit S, Boonyanaruthee V, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. *Drug Design, Development and Therapy*. 2016;10:259-76.doi: 10.2147/DDDT.S89485
32. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: Management: NICE; 2019 [cited 2020 06/02]. Available from: <https://www.nice.org.uk/guidance/cg113/chapter/1-Guidance>.
33. Taylor DM, Paton C, Kapur S. *The Maudsley prescribing guidelines in psychiatry*. 13th ed. West Sussex, England: Wiley Blackwell; 2018.
34. Villarreal G, Hamner MB, Canive JM, Robert S, Calais LA, Durklaski V, et al. Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. *The American journal of psychiatry*. 2016;173(12):1205-12.doi: 10.1176/appi.ajp.2016.15070967
35. Psychotropic Expert Group. Posttraumatic mental health disorders [cited 2023 14 Feb]. Available from: [https://tqldcdp.tg.org.au/viewTopic?topicfile=anxiety-disorders#toc\\_d1e1116](https://tqldcdp.tg.org.au/viewTopic?topicfile=anxiety-disorders#toc_d1e1116).
36. Hancock-Johnson E, Griffiths C, Picchioni M. A Focused Systematic Review of Pharmacological Treatment for Borderline Personality Disorder. *CNS Drugs*. 2017;31(5):345-56.doi: 10.1007/s40263-017-0425-0
37. Psychotropic Expert Group. Personality Disorders [cited 2023 14 Feb]. Available from: [https://tqldcdp.tg.org.au/viewTopic?topicfile=personality-disorders#toc\\_d1e145](https://tqldcdp.tg.org.au/viewTopic?topicfile=personality-disorders#toc_d1e145).
38. Lind KE, Raban MZ, Georgiou A, Westbrook JI. Duration of antipsychotic medication use by aged care facility residents with dementia. *Alzheimer Dis Assoc Disord*. 2019;33(4):331-8.doi: 10.1097/wad.0000000000000336

39. Yunusa I, Rashid N, Demos GN, Mahadik BS, Abler VC, Rajagopalan K. Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis. *Advances in Therapy*. 2022;39(5):1993-2008.doi: 10.1007/s12325-022-02075-8
40. El-Saifi N, Moyle W, Jones C, Tuffaha H. Quetiapine safety in older adults: a systematic literature review. *Journal of clinical pharmacy and therapeutics*. 2016;41(1):7-18.doi: 10.1111/jcpt.12357
41. Hershey LA, Coleman-Jackson R. Pharmacological Management of Dementia with Lewy Bodies. *Drugs Aging*. 2019;36(4):309-19.doi: 10.1007/s40266-018-00636-7
42. Stinton C, McKeith I, Taylor J-P, Lafortune L, Mioshi E, Mak E, et al. Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. *American Journal of Psychiatry*. 2015;172(8):731-42.doi: 10.1176/appi.ajp.2015.14121582
43. Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. *Lancet (London, England)*. 2015;386(10004):1683-97.doi: [https://doi.org/10.1016/S0140-6736\(15\)00462-6](https://doi.org/10.1016/S0140-6736(15)00462-6)
44. Taylor J-P, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, et al. New evidence on the management of Lewy body dementia. *Lancet neurology*. 2020;19(2):157-69.doi: 10.1016/S1474-4422(19)30153-X
45. The Lancet Neurology Editorial Team. Difficult choices in treating Parkinson's disease psychosis. *The Lancet Neurology*. 2018;17(7):569.doi: 10.1016/S1474-4422(18)30209-6
46. Psychotropic Expert Group. Parkinson disease [cited 2023 07 Feb]. Available from: [https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Neurology&topicfile=parkinson-disease&guidelinename=Neurology&sectionId=toc\\_d1e115#toc\\_d1e115](https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Neurology&topicfile=parkinson-disease&guidelinename=Neurology&sectionId=toc_d1e115#toc_d1e115).
47. Chen JJ, Hua H, Massihi L, Portillo I, Alipour A, Ondo W, et al. Systematic Literature Review of Quetiapine for the Treatment of Psychosis in Patients With Parkinsonism. *The Journal of Neuropsychiatry and Clinical Neurosciences*. 2019;31(3):188-95.doi: 10.1176/appi.neuropsych.18080180
48. Isaacson SH, Citrome L. Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions. *Expert Opinion on Drug Safety*. 2022;21(7):873-9.doi: 10.1080/14740338.2022.2069240
49. Desmarais P, Massoud F, Filion J, Nguyen QD, Bajsarowicz P. Quetiapine for Psychosis in Parkinson Disease and Neurodegenerative Parkinsonian Disorders: A Systematic Review. *Journal of Geriatric Psychiatry and Neurology*. 2016;29(4):227-36.doi: 10.1177/0891988716640378
50. Neurology Expert Group. Neuropsychiatric symptoms in Parkinson disease [cited 2020 06/02]. Available from: [https://tgldcdp.tg.org.au/viewTopic?topicfile=parkinson-disease&guidelineName=Neurology&topicNavigation=navigateTopic#toc\\_d1e349](https://tgldcdp.tg.org.au/viewTopic?topicfile=parkinson-disease&guidelineName=Neurology&topicNavigation=navigateTopic#toc_d1e349).
51. Psychotropic Expert Group. Dementia [cited 2023 07 Feb]. Available from: [https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Psychotropic&topicfile=dementia&guidelinename=Psychotropic&sectionId=toc\\_d1e47#toc\\_d1e47](https://tgldcdp.tg.org.au/viewTopic?etgAccess=true&guidelinePage=Psychotropic&topicfile=dementia&guidelinename=Psychotropic&sectionId=toc_d1e47#toc_d1e47).
52. Australian Commission on Safety and Quality in Health Care. 5.5 Antipsychotic medicines dispensing 65 years and over [cited 2020 May 07]. Available from: [https://www.safetyandquality.gov.au/publications-and-resources/australian-atlas-healthcare-variation-series#third-atlas-\(2018\)-by-topic](https://www.safetyandquality.gov.au/publications-and-resources/australian-atlas-healthcare-variation-series#third-atlas-(2018)-by-topic).
53. Royal Australian College of General Practitioners. Prescribing drugs of dependence in general practice, Part A – Clinical governance framework [cited 2019 Aug 1]. Available from: <https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/drugs-of-dependence>.
54. NPS MedicineWise. Antipsychotic monitoring tool [cited 2020 3 Mar]. Available from: <https://resources.amh.net.au/public/antipsychotic-monitoring-tool.pdf>.
55. Carr CN, Lopchuk S, Beckman ME, Baugh TB. Evaluation of the use of low-dose quetiapine and the risk of metabolic consequences: A retrospective review. *Ment Health Clin*. 2016;6(6):308-13.doi: 10.9740/mhc.2016.11.308
56. Pharmaceutical Benefits Scheme. Anti-psychotic medicines: 24 month review of quetiapine 25mg [cited 2020 30 Jun]. Available from: <http://www.pbs.gov.au/info/industry/listing/participants/public-release-docs/2016-09/antipsychotic-medicines-and-25mg-quetiapine-24-month-review-2016-09>
57. Pennington Institute. Australia's annual overdose report 2019. Carlton, VIC: Pennington Institute; 2019 [cited 2019 30 August]. Available from: <http://www.pennington.org.au/australias-annual-overdose-report-2019/>.
58. Pilgrim J, Drummer O. The toxicology and comorbidities of fatal cases involving quetiapine. *Forensic Science, Medicine, and Pathology*. 2013;9(2):170-6.doi: 10.1007/s12024-012-9404-4

59. Vedal TSJ, Steen NE, Birkeland KI, Dieset I, Reponen EJ, Laskemoen JF, et al. Free thyroxine and thyroid-stimulating hormone in severe mental disorders: A naturalistic study with focus on antipsychotic medication. *Journal of Psychiatric Research*. 2018;106:74-81.doi: <https://doi.org/10.1016/j.jpsychires.2018.09.014>
60. Lambert CG, Mazurie AJ, Lauve NR, Hurwitz NG, Young SS, Obenchain RL, et al. Hypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohort. *Bipolar Disorders*. 2016;18(3):247-60.doi: 10.1111/bdi.12391
61. Juraschek SP, Daya N, Appel LJ, Miller ER, 3rd, McEvoy JW, Matsushita K, et al. Orthostatic Hypotension and Risk of Clinical and Subclinical Cardiovascular Disease in Middle-Aged Adults. *J Am Heart Assoc*. 2018;7(10).doi: 10.1161/jaha.118.008884
62. MIMS Australia. APO-Quetiapine [cited 2019 27 Nov]. Available from: <http://www.mims.com.au>.
63. Datapharm. Seroquel 25 mg, 100 mg, 200 mg, 300 mg film-coated tablets [cited 2019 09 Dec]. Available from: <https://www.medicines.org.uk/emc/product/5495/smpc>.
64. Srivastava A, Patil V, Da Silva Pereira Y. A case series of quetiapine addiction/dependence. *German Journal of Psychiatry*. 2013;16(4):152-5.doi: 10.1177/0004867420965693
65. Monahan K, Cuzens-Sutton J, Siskind D, Kisely S. Quetiapine withdrawal: A systematic review. *The Australian and New Zealand journal of psychiatry*. 2021;55(8):772-83.doi: 10.1177/0004867420965693
66. Cubała WJ, Springer J. Quetiapine abuse and dependence in psychiatric patients: a systematic review of 25 case reports in the literature. *Journal of Substance Use*. 2014;19(5):388-93.doi: 10.3109/14659891.2013.810309
67. Srivastava A, Patil V, Da Silva Pereira Y. A case series of quetiapine addiction/dependence. *German Journal of Psychiatry*. 2013 [cited 2020 30 June]; 16(4):[152-5 p.]^pp.]. Available from: [https://www.researchgate.net/publication/289713538\\_A\\_case\\_series\\_of\\_quetiapine\\_addictiondependence](https://www.researchgate.net/publication/289713538_A_case_series_of_quetiapine_addictiondependence)
68. Yargic I, Caferov C. Quetiapine dependence and withdrawal: A case report. *Substance Abuse*. 2011;32(3):168-9.doi: 10.1080/08897077.2011.558448
69. Fanoë S, Kristensen D, Fink-Jensen A, Jensen HK, Toft E, Nielsen J, et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. *European Heart Journal*. 2014;35(20):1306-15.doi: 10.1093/eurheartj/ehu100
70. Buss VH, Lee K, Naunton M, Peterson GM, Kosari S. Identification of Patients At-Risk of QT Interval Prolongation during Medication Reviews: A Missed Opportunity? *Journal of Clinical Medicine*. 2018;7(12):533.doi: 10.3390/jcm7120533
71. Le Daré B, Ferron P-J, Allard P-M, Clément B, Morel I, Gicquel T. New insights into quetiapine metabolism using molecular networking. *Scientific Reports*. 2020;10(1):19921.doi: 10.1038/s41598-020-77106-x
72. Drug and Alcohol Services South Australia. Insomnia management kit: Instructions for GPs [cited 2021 3 Mar]. Available from: <https://www.sahealth.sa.gov.au/wps/wcm/connect/dc7255004033d45c9663bfd30eb2c8cd/1+-+Instructions+for+GPs+2017.pdf?MOD=AJPERES&CACHEID=ROOTWORKSPACE-dc7255004033d45c9663bfd30eb2c8cd-niQFXvG>.
73. Insight Centre for AOD Training and Workforce Development. Quetiapine and substance use. Helpful or hazardous? Anita Myers [cited 2021 3 Mar]. Available from: <https://insight.qld.edu.au/training/quetiapine-and-substance-use-helpful-or-hazardous/detail>.